NURS 5240 Pharmacology I Collaboration Comprehensive
QUESTION Bank | 500+ Most Tested QUESTIONs with Verified
Answers
QUESTION 1
A patient is prescribed a drug that undergoes extensive first-pass
hepatic metabolism. What is the primary clinical implication of this
pharmacokinetic property?
• A. The drug can only be administered via intravenous infusion.
• B. A significantly higher oral dose is required compared to its
intravenous dose to achieve therapeutic plasma levels.
• C. The drug will bypass the liver entirely via renal excretion.
• D. The drug has a 100% oral bioavailability.
Correct Answer: B. A significantly higher oral dose is required compared
to its intravenous dose to achieve therapeutic plasma levels.
Detailed Rationale: The first-pass effect refers to the substantial hepatic
inactivation of an orally administered drug before it reaches systemic
circulation. Consequently, oral medications subject to high first-pass
metabolism require higher dosages than parenteral routes to ensure
adequate bioavailability.
QUESTION 2
A pharmacologist is evaluating a newly developed competitive
antagonist. Which of the following characteristics best describes how a
competitive antagonist interacts with a receptor?
, • A. It permanently binds covalently to the receptor, rendering it
permanently inactive.
• B. It binds reversibly to the same receptor site as the agonist,
shifting the agonist dose-response curve to the right without
reducing maximal efficacy.
• C. It binds to an allosteric site, reducing the maximal efficacy of
the agonist regardless of concentration.
• D. It produces the opposite physiological effect of an agonist by
activating a separate receptor subtype.
Correct Answer: B. It binds reversibly to the same receptor site as the
agonist, shifting the agonist dose-response curve to the right without
reducing maximal efficacy.
Detailed Rationale: Competitive antagonists bind reversibly to active
receptor sites. Because the binding is surmountable, increasing the
concentration of the agonist can overcome the blockade, preserving
maximal efficacy while requiring a higher dose (surmountability).
QUESTION 3
A nurse practitioner is reviewing medication options for a patient with
hypertension and concurrent severe asthma. Which class of
antihypertensive medications is strictly contraindicated due to the risk
of precipitating severe bronchospasm?
• A. Non-selective beta-adrenergic antagonists (e.g., propranolol)
• B. Angiotensin-converting enzyme (ACE) inhibitors
• C. Dihydropyridine calcium channel blockers
, • D. Thiazide diuretics
Correct Answer: A. Non-selective beta-adrenergic antagonists (e.g.,
propranolol)
Detailed Rationale: Non-selective beta-blockers block both beta-1
receptors (cardiac) and beta-2 receptors (bronchial smooth muscle).
Blocking beta-2 receptors leads to bronchoconstriction, making them
dangerous for patients with asthma or chronic obstructive pulmonary
disease (COPD).
QUESTION 4
A patient taking an ACE inhibitor for heart failure reports a persistent,
dry, hacking cough. What is the underlying biochemical mechanism
responsible for this adverse drug reaction?
• A. Accumulation of histamine and serotonin in pulmonary tissues
• B. Decreased production of acetylcholine in the upper airway
• C. Accumulation of bradykinin and substance P due to the
inhibition of kininase II
• D. Upregulation of beta-2 adrenergic receptors in the bronchioles
Correct Answer: C. Accumulation of bradykinin and substance P due to
the inhibition of kininase II
Detailed Rationale: ACE inhibitors inhibit the enzyme kininase II, which
is responsible for breaking down bradykinin. The resulting buildup of
bradykinin and substance P in the lungs triggers C-fiber nerve endings,
causing the characteristic dry cough associated with ACE inhibitors.
QUESTION 5
, Which of the following calcium channel blockers exhibits significant
selectivity for cardiac myocardial tissue and the atrioventricular (AV)
node, making it effective for rate control in atrial fibrillation?
• A. Amlodipine
• B. Nifedipine
• C. Diltiazem
• D. Felodipine
Correct Answer: C. Diltiazem
Detailed Rationale: Non-dihydropyridine calcium channel blockers like
diltiazem and verapamil exert profound negative chronotropic and
dromotropic effects on the heart, targeting cardiac calcium channels.
Dihydropyridines (e.g., amlodipine) act primarily on vascular smooth
muscle to cause vasodilation.
QUESTION 6
A patient with acute decompensated heart failure and severe fluid
overload is prescribed intravenous furosemide. Where is the primary
site of action for loop diuretics within the nephron?
• A. Proximal convoluted tubule
• B. Ascending limb of the loop of Henle
• C. Early distal convoluted tubule
• D. Collecting duct
Correct Answer: B. Ascending limb of the loop of Henle
QUESTION Bank | 500+ Most Tested QUESTIONs with Verified
Answers
QUESTION 1
A patient is prescribed a drug that undergoes extensive first-pass
hepatic metabolism. What is the primary clinical implication of this
pharmacokinetic property?
• A. The drug can only be administered via intravenous infusion.
• B. A significantly higher oral dose is required compared to its
intravenous dose to achieve therapeutic plasma levels.
• C. The drug will bypass the liver entirely via renal excretion.
• D. The drug has a 100% oral bioavailability.
Correct Answer: B. A significantly higher oral dose is required compared
to its intravenous dose to achieve therapeutic plasma levels.
Detailed Rationale: The first-pass effect refers to the substantial hepatic
inactivation of an orally administered drug before it reaches systemic
circulation. Consequently, oral medications subject to high first-pass
metabolism require higher dosages than parenteral routes to ensure
adequate bioavailability.
QUESTION 2
A pharmacologist is evaluating a newly developed competitive
antagonist. Which of the following characteristics best describes how a
competitive antagonist interacts with a receptor?
, • A. It permanently binds covalently to the receptor, rendering it
permanently inactive.
• B. It binds reversibly to the same receptor site as the agonist,
shifting the agonist dose-response curve to the right without
reducing maximal efficacy.
• C. It binds to an allosteric site, reducing the maximal efficacy of
the agonist regardless of concentration.
• D. It produces the opposite physiological effect of an agonist by
activating a separate receptor subtype.
Correct Answer: B. It binds reversibly to the same receptor site as the
agonist, shifting the agonist dose-response curve to the right without
reducing maximal efficacy.
Detailed Rationale: Competitive antagonists bind reversibly to active
receptor sites. Because the binding is surmountable, increasing the
concentration of the agonist can overcome the blockade, preserving
maximal efficacy while requiring a higher dose (surmountability).
QUESTION 3
A nurse practitioner is reviewing medication options for a patient with
hypertension and concurrent severe asthma. Which class of
antihypertensive medications is strictly contraindicated due to the risk
of precipitating severe bronchospasm?
• A. Non-selective beta-adrenergic antagonists (e.g., propranolol)
• B. Angiotensin-converting enzyme (ACE) inhibitors
• C. Dihydropyridine calcium channel blockers
, • D. Thiazide diuretics
Correct Answer: A. Non-selective beta-adrenergic antagonists (e.g.,
propranolol)
Detailed Rationale: Non-selective beta-blockers block both beta-1
receptors (cardiac) and beta-2 receptors (bronchial smooth muscle).
Blocking beta-2 receptors leads to bronchoconstriction, making them
dangerous for patients with asthma or chronic obstructive pulmonary
disease (COPD).
QUESTION 4
A patient taking an ACE inhibitor for heart failure reports a persistent,
dry, hacking cough. What is the underlying biochemical mechanism
responsible for this adverse drug reaction?
• A. Accumulation of histamine and serotonin in pulmonary tissues
• B. Decreased production of acetylcholine in the upper airway
• C. Accumulation of bradykinin and substance P due to the
inhibition of kininase II
• D. Upregulation of beta-2 adrenergic receptors in the bronchioles
Correct Answer: C. Accumulation of bradykinin and substance P due to
the inhibition of kininase II
Detailed Rationale: ACE inhibitors inhibit the enzyme kininase II, which
is responsible for breaking down bradykinin. The resulting buildup of
bradykinin and substance P in the lungs triggers C-fiber nerve endings,
causing the characteristic dry cough associated with ACE inhibitors.
QUESTION 5
, Which of the following calcium channel blockers exhibits significant
selectivity for cardiac myocardial tissue and the atrioventricular (AV)
node, making it effective for rate control in atrial fibrillation?
• A. Amlodipine
• B. Nifedipine
• C. Diltiazem
• D. Felodipine
Correct Answer: C. Diltiazem
Detailed Rationale: Non-dihydropyridine calcium channel blockers like
diltiazem and verapamil exert profound negative chronotropic and
dromotropic effects on the heart, targeting cardiac calcium channels.
Dihydropyridines (e.g., amlodipine) act primarily on vascular smooth
muscle to cause vasodilation.
QUESTION 6
A patient with acute decompensated heart failure and severe fluid
overload is prescribed intravenous furosemide. Where is the primary
site of action for loop diuretics within the nephron?
• A. Proximal convoluted tubule
• B. Ascending limb of the loop of Henle
• C. Early distal convoluted tubule
• D. Collecting duct
Correct Answer: B. Ascending limb of the loop of Henle
